Inactive Instrument

Other languages Meridian Bioscience, Inc.

Equities

VIVO

US5895841014

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits	Apr. 10
Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex	23-07-25
Meridian Bioscience, Inc. Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay	23-04-19
Meridian Bioscience, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-09
SD BioSensor, Inc and SJL Partners completed the acquisition of Meridian Bioscience, Inc. from Impactive Capital LP, BlackRock, Inc., The Vanguard Group, Inc, Royce & Associates, LP and others.	23-01-30
DoubleVerify Holdings to Replace Meridian Bioscience in S&P SmallCap 600	23-01-26
Meridian Bioscience Says Closing Date of Pending Merger With SD Biosensor, Others Pushed Back to Jan. 31	22-12-12
Meridian Bioscience Fiscal Q4 Adjusted EPS, Revenue Decline	22-11-22
Meridian Bioscience, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-22
Meridian Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2022	22-11-22
Impactive Capital Provides Information to Shareholders of Meridian Bioscience	22-10-28
Meridian Bioscience Posts Decline in Fiscal Q3 Adjusted Net Earnings, Higher Revenue, Scraps 2022 Guidance	22-08-05
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Posts Q3 Revenue $67.8M	22-08-05
Meridian Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-05
Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022	22-08-05
Meridian Bioscience Gets FDA Re-Authorization for Revogene COVID-19 Test	22-07-29
Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay	22-07-29
Meridian Bioscience Reports Fiscal Q3 Preliminary Revenue; Shares Halted on Acquisition News	22-07-07
South Korean consortium to buy Meridian Bioscience in $1.53 billion deal	22-07-07
Meridian Bioscience, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal 2022	22-07-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Meridian Bioscience, Inc.

Equities

VIVO

US5895841014

Other languages

Filters